Research literature

CBL-514 Explained: What the Phase 2b Fat-Reduction Data Show and What They Do Not

Published October 23, 2026 · 8 min read

Most weight-loss research measures the whole body. CBL-514 is being studied for a narrower question: whether an injected small molecule can reduce fat in a specific area. The developer, Caliway Biopharmaceuticals, has reported phase 2 results, started phase 3 trials and, in 2026, begun testing the compound alongside a GLP-1-type drug. This article walks through what has actually been published, what has only been announced, and what the evidence cannot yet say.

What CBL-514 is

CBL-514 is a small-molecule injection developed by Caliway Biopharmaceuticals (New Taipei City, Taiwan) for localized fat reduction and, in separate studies, cellulite. The company describes it as a first-in-class compound that "selectively induces adipocyte apoptosis," meaning it is intended to cause fat cells to die in a controlled way, which would reduce the number of fat cells rather than only shrinking them (source 5). It says the compound reduces fat at the injection site without necrosis or damage to surrounding tissue (source 5). Those are the company's statements. We did not find an independent peer-reviewed mechanism study to confirm them, so treat the mechanism as a developer claim.

It differs from the better-known weight-loss drugs in two ways. It is given by injection into a defined area rather than acting through appetite or metabolic hormones, and its target is local fat volume rather than total body weight.

The phase 2b trial in abdominal fat

The main peer-reviewed report is a randomized, single-blind, placebo-controlled phase 2b trial (NCT05736107) published in Aesthetic Surgery Journal in 2026 (source 1). It enrolled 108 adults with moderate to severe abdominal subcutaneous fat, randomized 1:1 to CBL-514 (53) or placebo (55). Participants received up to four treatments three weeks apart, with follow-up at 4, 8 and 12 weeks after the last treatment. A company release from December 2024 describes the same trial (source 2).

The primary endpoint was a clinician-rated improvement of at least one grade on a fat rating scale (CR-AFRS) 12 weeks after the last treatment. A rating scale is a judgment, not a measurement, which is why the trial also included MRI.

At the earlier 4-week point, the MRI change was larger, -20.3% (-152.9 mL) versus +0.1% for placebo (source 1). That the effect looks bigger at 4 weeks than at 12 is worth noticing: it suggests some of the early change may not last, or that early measurements include swelling or fluid from the injections. The paper cannot tell us which.

Reading the numbers carefully

Two details in the paper deserve a pause. First, the denominators in the main analysis are small relative to the 108 people randomized (30 and 37 in the text), and the paper's own figure shows different counts (49 and 51). We could not reconcile the two from the text we read, so the exact analysis populations are unclear. Second, 43.4% of the treated group and 34.5% of the placebo group left the study early, mostly because of protocol requirements such as keeping weight stable and attending visits, and missing data were filled in using last observation carried forward (source 1). Both facts mean the headline percentages should be read as a signal from a small, imperfect analysis, not a precise estimate. For how to weigh analysis populations and missing data, see How to Read a Clinical Trial Result.

What the trial reported on safety

Injection-site reactions were very common and more frequent with CBL-514 than with placebo (source 1):

Four people in the CBL-514 group stopped because of adverse events (hives in three, pain in one) versus one in the placebo group. Two serious adverse events, both fractures, were judged unrelated to treatment, and no life-threatening or fatal events were reported (source 1). Company releases describe the side-effect profile as favorable and the reactions as mild to moderate (source 2); the table above shows why the numbers matter more than the adjective. The authors note that splenic imaging was not performed.

Visceral fat: a conference report

At the September 2026 EASD meeting, an analysis of two phase 2 trials (CBL-0204 and CBL-0205) reported MRI changes in visceral fat, the fat around internal organs, in a subgroup of adults with a BMI of 22 to 30 (source 3). As summarized by News-Medical, treated participants (23 at baseline) had a 12.01% fall in visceral fat four weeks after the last treatment versus a 5.68% rise with placebo, and a 10.45% fall versus an 11.76% rise at the later follow-up (source 3). The summary says the injections were given into the lower abdomen. This is a subgroup analysis presented at a congress, co-authored by a Caliway executive, and we did not find a peer-reviewed version. Subgroup analyses of this kind are hypothesis-generating. The same summary reports that, in animal models, adding CBL-514 to tirzepatide produced more weight loss and less regain after stopping tirzepatide; animal results do not establish what happens in people (source 3).

What is in development now

According to company releases and trade coverage, three studies are underway or cleared:

• SUPREME-02 (CBL-0302): a phase 3, randomized, double-blind, placebo-controlled trial of about 320 participants in the United States, Canada and Australia, with MRI-measured abdominal subcutaneous fat volume and a patient-rated fat scale as primary endpoints. The FDA's 30-day review of its IND passed on May 18, 2026, and the company expects results in 2027 (source 4).
• SUPREME-01 (CBL-0301): a second pivotal phase 3 trial. Per an August 25, 2026 company release, a central ethics board approved its protocol amendment and enrollment began; the release states a goal of a 2-grade improvement on the fat rating scale but does not disclose sample size or other endpoints (source 5).
• CBL-0201WR: a planned phase 2, randomized, single-blind, placebo-controlled study of about 120 US adults combining CBL-514 with tirzepatide, with MRI abdominal subcutaneous fat volume as the efficacy endpoint and body weight, visceral fat and lean mass as exploratory endpoints. The FDA cleared the IND, but the release does not confirm that enrollment has started (source 5).

The company also states that across 10 completed clinical trials involving 544 participants the studies met all efficacy and safety endpoints (source 4). That is a sponsor summary, not a pooled independent analysis.

Limitations of the evidence so far

• The only peer-reviewed human efficacy data we found are from one phase 2b trial of 108 people, with co-authors employed by the developer (source 1).
• The trial was single-blind, so raters or participants may have known more than a double-blind design would allow. Clinician and patient ratings are subjective; MRI is the stronger measure.
• Large dropout and the use of last observation carried forward limit how precisely the effect size can be stated.
• The follow-up ended 12 weeks after the last treatment, so durability beyond that is not shown.
• Injection-site reactions were near-universal. Longer-term safety, effects on other tissues, and the consequences of repeated treatment are not established.
• The visceral-fat and tirzepatide-combination findings come from a conference summary and animal models, not peer-reviewed human trials.
• Most efficacy and mechanism claims come from the sponsor's own releases and have not been independently replicated.

The short version

CBL-514 has a placebo-controlled phase 2b result in abdominal subcutaneous fat, measured partly by MRI, from a small trial with high dropout and developer-affiliated authors. Injection-site reactions were very common, and the effect appeared larger at 4 weeks than at 12. Larger double-blind phase 3 trials are enrolling, and the combination with a GLP-1-type drug is at an early stage. The honest reading is "a signal worth testing in bigger trials," not a settled result. If phase 3 data or peer-reviewed visceral-fat results appear, this article will be updated. For how to weigh claims at this stage, see Personal Accounts vs. Trial Data.

Sources

• Lorenc ZP, Gold M, Schlessinger J, et al. Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-Reported Outcomes and MRI Assessment. Aesthetic Surgery Journal, 2026. doi:10.1093/asj/sjag092. academic.oup.com
• Caliway Biopharmaceuticals, "Caliway Announces Successful Study Results from CBL-0204, a CBL-514 Phase 2b Study for Reducing Abdominal Subcutaneous Fat," Dec 11, 2024 (company release, not peer-reviewed): prnewswire.com
• News-Medical, "CBL-514 injection reduces visceral and subcutaneous fat in trials," Oct 1, 2026 (summary of an EASD 2026 presentation; not a peer-reviewed paper): news-medical.net
• Modern Aesthetics, "FDA Clears Caliway's Phase 3 CBL-514 Trial for Abdominal Fat Reduction," May 22, 2026: modernaesthetics.com
• Caliway Biopharmaceuticals, release on the CBL-514 combination IND and SUPREME-01 enrollment, Aug 25, 2026 (company release): placera.se

Related reading

• How to Read a Clinical Trial Result
• Why "It Worked for Me" Isn't Evidence
• Tesamorelin Trial Results Explained
• Glossary

← Back to all articles